MSProfile™ identifies whether you're Th1, Th17, or B-cell dominant—so you start with the high-efficacy DMT most likely to work for YOUR MS.
Standard MS treatment starts with first-line DMTs like Copaxone or Avonex. If those fail after 12-18 months, you escalate to high-efficacy therapies. Meanwhile, new lesions form and disability progresses.
Test your neuroinflammatory pathways at diagnosis. If you're B-cell dominant, start Ocrevus immediately. If you're Th17-driven, consider Mavenclad. Don't waste 18 months on therapies that won't stop YOUR disease.
Select the level of analysis that's right for your MS
Core Panel
One-time payment
Newly diagnosed patients or those considering escalation to high-efficacy DMTs.
Full Details →Enhanced Panel
One-time payment
Highly active MS, failed multiple DMTs, or considering HSCT/Lemtrada.
Full Details →Don't waste time on first-line therapies that won't work for YOUR MS pathways.
Order Your Panel →